Horizon Kinetics Asset Management LLC Acquires 6,888 Shares of Pfizer Inc. (NYSE:PFE)

Horizon Kinetics Asset Management LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 100,703 shares of the biopharmaceutical company’s stock after purchasing an additional 6,888 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Pfizer were worth $2,672,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC purchased a new stake in Pfizer during the 4th quarter valued at $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the 4th quarter valued at about $28,000. Gladius Capital Management LP boosted its stake in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares in the last quarter. Finally, Noble Wealth Management PBC bought a new stake in shares of Pfizer during the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.5 %

Shares of Pfizer stock opened at $25.74 on Monday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $145.85 billion, a PE ratio of 18.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a 50-day simple moving average of $26.24 and a two-hundred day simple moving average of $27.12.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the company earned $0.10 earnings per share. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Activity

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.06% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, March 12th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.